Fibrinolytic inhibitors and fibrin characteristics determine a hypofibrinolytic state in patients with pulmonary embolism

Thrombosis and Haemostasis

Volumn 109, Issue 3, 2013, Pages 565-567

  Cellai, Anna Paola ^a   Lami, Donatella ^b   Antonucci, Emilia ^b   Fiorillo, Claudia ^b   Becatti, Matteo ^b   Olimpieri, Benedetta ^b   Bani, Daniele ^b   Grifoni, Elisa ^b   Cenci, Caterina ^b   Marcucci, Rossella ^b   Mannini, Lucia ^a   Poli, Daniela ^a   Abbate, Rosanna ^b   Prisco, Domenico ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING INHIBITOR; FIBRIN; FIBRINOGEN; ORAL CONTRACEPTIVE AGENT; PLASMIN; PROTHROMBIN;

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HUMAN; LETTER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION TESTS; FEMALE; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 84874773672     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-09-0648     Document Type: Letter

References (14)

1. Lisman T, de Groot PG, Meijers JCM, et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-1105.
2. Guimarães AH, de Bruijne EL, Lisman T, et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145: 115-120.
3. Meltzer ME, Doggen CJ, de Groot PG, et al. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol 2007; 14: 242-248.
4. Olman MA, Marsh JJ, Lang IM, et al. Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation 1992; 86: 1241-1248.
5. Lang IM, Marsh JJ, Olman MA, et al. Parallel analysis of tissue-type plasminogen activator and tipe 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation 1994; 90: 706-712.
6. Lang IM, Marsh JJ, Olman MA, et al. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-2721.
7. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5 (Suppl 1): 116-124.
8. Morris TA, Marsh JJ, Chiles PG, et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am J Respir Crit Care Med 2006; 173: 1270-1275.
9. Miniati M, Fiorillo C, Becatti M, et al. Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. Am J Respir Crit Care Med 2010; 181: 992-996.
10. Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Pathol 1958; 11: 403-405.
11. Lisman T, Leebeek FW, Mosnier LO, et al. Thrombin activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
12. Cellai AP, Lami D, Magi A, et al. Assessment of fibrinolytic activity by measuring the lysis time of a tissue factor-induced clot: a feasibility evaluation. Clin Appl Thromb Hemost 2010; 16: 337-344.
13. Meltzer ME, Lisman T, de Groot PG, et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. Blood 2010; 116: 113-121.
14. Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009; 114: 1929-1936.